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Cellular RNA exonucleases, such as XRN1 and DXO, aid in the destruction of defective 
cellular mRNAs and help maintain overall cellular health. The RNA decay system, however, also 
serves another purpose – degrading viral RNAs. The XRN1 exonuclease is known to be a major 
antagonist of RNA virus genomes, but the role of other cellular RNA decay enzymes in 
controlling viral infection is less clear. The cellular 5’ decapping exonuclease DXO is able to 
recognize, de-cap, and degrade RNAs lacking 2’-O-methylation on the first nucleotide after the 
5’ cap, helping the cell to discriminate self from non-self RNAs. Preliminary data we have 
developed indicate that flaviviruses and alphaviruses replicate to much higher levels in DXO 
deficient cells than in cells containing DXO, indicating that DXO may also act as a cellular viral 
restriction factor. Interestingly, flavivirus genomes contain a 5’ cap that is generally 2’-O-
methylated at the first base of the transcript, providing a potential mechanism to evade DXO 
degradation. Overall, our results indicate that the DXO decapping exonuclease helps control the 
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Flaviviruses and Alphaviruses: A Global Health Problem 
 Viruses that fall under the alphavirus and flavivirus genera continue to be a major health 
threat across the globe. Approximately thirty-five of the seventy known flaviviruses are 
associated with disease in humans and an estimated two-thirds of the world’s population is 
affected by such viruses1. Transmitted primarily through mosquitoes, these viruses are highly 
prevalent in the tropics and underdeveloped countries.  Due to the significantly high number of 
infections, the costs of health services as well as to the economies of affected countries have 
increased substantially. Those living in impoverished countries are more susceptible to 
flaviviruses and alphaviruses due to poorer living conditions and insufficient access to treatment. 
Flavivirus disease can cause serious morbidity and mortality in afflicted areas, and these viruses 
represent a serious global health concern.  
 Dengue virus (DENV), known to cause the disease “break-bone fever”, is one of the most 
prevalent of the flaviviruses with over one-third of the world’s population at risk of infection2. 
Dengue viruses are transmitted by Aedes aegypti mosquitoes, which are relevantly wide-spread 
geographically3. There are four separate serotypes of DENV that co-circulate, each causing a 
range of symptoms and disease3. The majority of infections are asymptomatic or cause mild 
disease such as fever but those who experience a secondary DENV infection increase their risk 
of developing more severe disease such as hemorrhagic fever or dengue shock syndrome3. There 
is no cross-protection between serotypes, and when the host immune system is primed against 
one DENV serotype, subsequent DENV infections with different serotypes leads to worse 
disease via a process known as antibody-dependent enhancement (ADE) 4,5. ADE can lead to 
dengue shock syndrome and dengue hemorrhagic fever, both of which have high mortality rates. 
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Making a vaccine against DENV has shown to be difficult as it needs to protect against all four 
serotypes without leading to ADE, resulting in very slow development of safe and effective 
vaccines against these serious pathogens.  
 Zika virus (ZIKV) first emerged as an epidemic in 2015 in Brazil and caused panic as 
disease such as microcephaly in babies and Guillain-Barre syndrome in adults were linked to 
infections6,7. ZIKV was shown to be spreading through the Americas with a few cases being 
reported in Africa and Asia. ZIKV is transmitted through the A. aegypti mosquito and can then 
be transmitted from mother to fetus. The most common symptoms associated with ZIKV are 
nonspecific diseases such as a fever or rash and diagnostics specific to ZIKV are not available in 
lesser-developed countries8. Mechanisms behind ZIKV infections are still not well-understood as 
there continues to be a need for effective antiviral therapeutics as well as cheaper and easier to 
use diagnostic tools.  
 Yellow fever virus (YFV) has re-emerged within the last several years as a health threat 
in South America and central Africa. Yellow fever virus was first identified in Africa and 
introduced to the Americas during the 15th or 16th century9. Approximately 200,000 cases of 
YFV arise every year with 15% of infections leading to death10. YFV can lead to lesions of the 
liver, kidney, or heart and with more serious infections, death11. There are vaccines available 
against YFV however they are not easily accessible in underdeveloped countries. Approximately 
393 to 427 million people living in YFV risk zones are still in need vaccinations in order for 80% 
of the population to be covered12.  Due to the most recent outbreaks in countries such as Brazil 
and Nigeria, there is a need for further elucidation of YFV replication to learn how to contain 
and prevent the virus more effectively.  
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 One flavivirus that continues to cause problems within the United States and Canada is 
West Nile Virus (WNV). WNV is transmitted by Culex mosquitoes and is maintained in nature 
by cycling through birds and mosquitoes13,14.  Once infected, WNV replicates within multiple 
tissues including in the brain. WNV can cause a variety of flu-like symptoms including fever, 
rash, and even vomiting while less than one percent experience neuroinvasive disease15. 
Currently there are no vaccines or therapeutic antivirals available for WNV and prevention relies 
on managing mosquito populations or using insect repellent. WNV is one the largest arboviral 
outbreaks recorded in the U.S. and the highest number of infections are found in the Midwest 
during the Summer15. While surveillance of mosquitoes and WNV incidents in the community 
can help contain an outbreak, development of a vaccine would be much more effective.   
 Similar to flaviviruses, alphaviruses are mosquito-transmitted arboviruses that pose a 
threat worldwide.  Chikungunya virus (CHIKV) is the main example of a globally-relevant 
alphavirus. The word Chikungunya comes from East Africa and means “that which bends up” 
due to the severe joint pain and swelling the virus induces along with a fever and rash16. One of 
the first CHIKV cases was reported in 1952 in Tanzania and has since spread throughout Africa, 
Asia, Europe, and the Americas16,17. Various pain medications can be administered to patients 
experiencing severe joint pain but no vaccines or therapeutic treatments have been approved for 
human use18. CHIKV is commonly spread through the A. aegypti mosquito found primarily in 
tropical and subtropical regions19. More recently the virus has evolved to replicate in other 
mosquitoes such as Aedes albopictus thus allowing it to spread past these tropical regions into 
more temperate locations, significantly increasing the number of those at risk of infection19.  
 An alphavirus that could cause the next major outbreak is Mayaro virus (MAYV). 
MAYV is commonly mistaken for CHIKV as it causes a fever as well as severe joint pain and 
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swelling20. Severe infections lead can lead to hemorrhage, inflammation of the heart muscle, and 
death21.  MAYV circulates between Hemagogus janthinomys mosquitoes and non-human 
primates21. The virus is primarily found in neotropical cities and has been isolated from 
mosquitoes, humans, lizards, and birds22. Currently only a few minor outbreaks have been 
recorded but there is a continuous increase in infections reported in Brazil20. To further 
understand MAYV on a molecular level may aid in containing any future outbreak. 
 Unlike other alphaviruses discussed, Venezuelan Equine encephalitis virus (VEEV) not 
only can cause outbreaks but can also be used as a biological warfare agent when aerosolized23. 
As the name suggests the virus causes severe encephalitis and replicates within the lymph nodes, 
heart, lung, kidney and pancreas24. IA/B, IC, ID, and IE are the four antigenic varieties of VEEV 
but are indistinguishable from one another23. The virus can be maintained in nature by 
circulating through rodents and mosquitoes while the cause outbreaks in humans and horses23. 
VEEV has been reported in North, Central, and South America while both the U.S. and the 
former Soviet Union has developed a biological weapon from the virus25. Vaccines against 
VEEV is crucial for protection from outbreaks and attacks using the virus as a weapon. The 
vaccine must provide protection at differing routes of infection both subcutaneous and aerosol to 
be the most effective.   
 Each of these aforementioned viruses cause significant human disease, but there is a 
general lack of effective vaccines and antivirals to treat infections. Developing a better 
understanding of how these viruses replicate and interact with the cell will help in the 
development of these therapies and may help to save lives. Since the occurrence of various viral 
outbreaks such as those mentioned, flavivirus and alphavirus research has advanced 
substantially. Despite being from different viral families and having a few minor genomic 
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differences, flaviviruses and alphaviruses share many similarities between their replication 
cycles. The infection begins when a virus attaches to a cell and undergoes receptor-mediated 
endocytosis. In the endosome, acidification occurs and triggers a conformational change in the 
viral glycoproteins that allow fusing of viral and cellular membranes26,27. This conformational 
change allows the virus to fuse its viral envelope to the endosomal membrane and release the 
viral RNA into the cytoplasm.  
Flavivirus genomes contain a 5’ cap that is N7-methylated as well as a 2’-O-methylated 
first base of the transcript and a stem loop structure at the 3’ end to terminate translation shown 
in Figure 1. Alphaviruses also contain a 5’ cap that is N7 but not 2’-O-methylated and a 3’ 
poly(A) tail. With the proper 5’ and 3’ molecular structures and modifications, the virus genomes 
resemble mRNA and can replicate using cellular translation machinery directly in the cytoplasm 
without further modifications. Flavivirus genomes are organized to express structural proteins at 
the 5’ end and nonstructural proteins at the 3’ end28. The nonstructural and structural proteins are 
translated into a single polyprotein before being translocated across the ER membrane. Viral and 
cellular proteases cleave the polyprotein into individual proteins where they can be modified in 
the ER. Following translation, nonstructural proteins such as NS3 and NS5 in flaviviruses 
 
Figure 1. Flavivirus and Alphavirus genomic structures. 
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replicate the viral genome while structural proteins begin to form the packaging for viral 
genomes26,27. Replication of flavivirus genomes and particle assembly occurs in vesicles located 
in the lumen of the ER28. Structural proteins such as capsid (C), pre-membrane (prM), and 
envelope (E) must undergo modifications in preparation for viral particle budding29. Once a 
particle buds from the ER, maturation must occur in the Golgi complex and prM is cleaved by 
furin protease. Cleavage of prM is crucial for the rearrangement of E proteins on the virion 
surface and maturation of the particle28,29. The matured viral particle buds from the Golgi and 
fuses with the cellular membrane through the structural proteins on the viral surface thus 
allowing viral budding from the cell29. 
Alphaviruses express a nonstructural polyprotein at the 5’ end and a structural 
polyprotein at the 3’ end28. During the early stage of translation the nonstructural polyprotein, 
P123, in the alphavirus genome is translated first. P123 is cleaved by the viral nsP2 protease and 
form a complex necessary for further viral genome replication as well as translation of structural 
polyproteins. Like flaviviruses, alphavirus polyproteins undergo cleavage by viral and cellular 
proteases and non-structural proteins are processed in the ER to form functional proteins26,27. The 
nonstructural protein, nsp4, replicates the viral genome that is packaged in a nucleocapsid26,27. 
During alphavirus genome packaging, structural glycoproteins such as PE2-E1 that form the 
spike complex undergo processing in the ER and Golgi apparatus28,30. Genomic RNA is 
subsequently packaged into capsids made up of capsid protein and trafficked to the plasma 
membrane for budding. The spike complex is transported to the plasma membrane where it is 
activated by the cellular furin protease and allows budding of the assembled alphavirus particle 
to occur28. Once a virus buds from the cell, the infectious particle is free to infect adjacent cells.  
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 One of the challenges for cells is to detect and destroy viral genomes during infections, 
which can be difficult when viral genomes look similar to cellular RNAs. Cellular mRNAs 
contain a 5’ 7-methylguanosine cap that is 2’-O-methylated and a 3’ poly-A tail which are all 
necessary for RNA transport, processing, and translation. Any RNAs that do not contain the 
appropriate modifications are recognized as defective and are degraded by the cellular RNA 
decay machinery31. The single-strand positive sense alphavirus and flavivirus genomes also 
contain a 5’ cap that is 2’-O-methylated in flaviviruses but not alphaviruses27,32. In addition, 
flaviviruses do not contain a 3’ poly(A) tail but instead terminate with a stem loop structure 
while alphaviruses do contain the appropriate 3’ poly(A) tail1. The genomes contain the 
necessary molecular features to be translated by the cell, however, they appear as defective 
mRNAs to the cellular RNA decay machinery due to missing cellular markers such as a ribose 
methylation or a poly(A) tail. With the decay machinery unable to recognize the viral RNA as 
self, it is likely targeted for degradation, making this pathway the cell’s first line of defense 
against infection. 
The Cellular RNA Decay Pathway  
Cellular RNA decay pathways regulate gene expressions through maintaining appropriate 
levels of mRNA transcripts to undergo translation and degrade faulty RNAs33. In order to sustain 
equilibrium, the cell must respond quickly to both internal and external cues through changing 
the abundance of mRNAs to be translated33,34. Each mRNA transcript is equipped with a 5’ cap 
and poly(A) tail to protect against degradation, however, these modifications are thoroughly 
scrutinized through a series of protein-protein and protein-RNA interactions. As the poly(A) tail 
undergoes a sufficient amount of deadenylation or the 5’ cap contains inadequate methylation, 
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these transcripts become susceptible to degradation. By degrading defective RNAs, the cell is 
protected against aberrant mutations or deletions that can have fatal downstream effects.   
To initiate the degradation of a specific transcript, deadenylation must first occur. The 
PAN2-PAN3 (PAN2/3) deadenylation complex catalyzes this process by deadenylating tails 
longer than approximately 150 bp until the CCR4-NOT (CNOT) deadenylation complex steps in 
to finish the job35. The PAN2/3 complex does not affect stability of the transcript and acts as a 
preliminary step36,37. Poly(A) binding proteins (PABP) bind to the poly(A) tail to increase 
transcript stability and prevent deadenylation of the tail38,39.  The catalytic subunit of CNOT, 
CAF1, deadenylates unbound poly(A) tail until it becomes blocked by a PABP. Upon CAF1 
stalling, the CCR4 catalytic subunit of CNOT becomes activated by the PABP and removes the 
RNA binding protein as it continues deadenylating39. The deadenylated transcript is subsequently 
uridylated by terminal uridylyltransferases (TUTases), promoting decapping and degradation of 
the transcript38,40.  
The 5’ cap provides mRNA transcripts the ability to undergo translocatation with the help 
of cellular factors from the nucleus to cytoplasm for translation, increases splicing efficiency, 
and protects from 5’ to 3’ exoribonucleases41. Removal of the 5’ cap via decapping enzymes 
plays a significant role in downstream expression of the transcript by marking it for decay41,42. 
The well-studied decapping enzyme DCP2 is responsible for removing the α- and β- phosphate 
of the cap and generating a monophosphorylated RNA transcript, a perfect substrate for a 5’ to 3’ 
exoribonuclease43. For DCP2 to be activated and target a transcript, there are a variety of 
cofactors that need to be present. For instance, the LSM1-7 complex binds to the deadenylated 
RNA and recruits DCP2 while the RNA helicase, DDX6, reassembles the transcript for optimal 
binding of proteins44,45. DCP2 was initially thought to be the primary decapping enzyme in 
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eukaryotes but was found to only affect a subset of transcripts42. Recent studies have shown 
other proteins possessing similar decapping activities such as the Nudix proteins, Nudt16 and 
Nudt3, and DXO46–48. Like DCP2, the Nudix proteins prefer a subset of transcripts while DXO 
targets transcripts with an incomplete 5’ cap47,49.  Nonetheless, there are many more decapping 
enzymes to be discovered, most of which are suspected to be a part of the Nudix family. With the 
5’ cap removed and a monophosphorylated transcript remaining, 5’ to 3’ or 3’ to 5’ 
exoribonucleases can begin to degrade the target mRNA.  
 While deadenylation and decapping are an efficient and more common means of marking 
a transcript for exonucleolytic decay, endonuclease activity can also lead to the same result. 
During active translation of an mRNA by ribosomes, endonucleases target a sequence or 
structure within the transcript for cleavage50,51. Once cleaved into smaller fragments, the RNA 
can be further degraded by 5’ to 3’ or 3’ to 5’ exonucleases52. There are multiple endonucleases 
associated with the polysome and RNA decay, such as PRM-1. Like other decay pathways, 
endonucleases are thoroughly regulated to prevent unwanted nucleolytic decay. For instance, 
PRM-1 must undergo phosphorylation by the tyrosine-protein kinase, Src (c-Src) to be targeted 
to the polysome and activated for endonucleolytic decay50. Hyperphosphorylation of serine 
residues on the endonuclease, GB3P, is imperative for its activity53. In addition to protein 
modifications, endonucleases such as Argonaute2 (Ago2) may be activated through the RNA 
interference (RNAi) pathway54. Through microRNAs and small interfering RNAs (siRNAs) 
produced by the dicer protein, Ago2 is guided to a target mRNA for subsequent cleavage55. This 
cleavage event leads to additional degradation by exonucleases.   
 With the 3’ end of a transcript exposed after deadenylation, 3’ to 5’ exoribonucleases can 
target the RNA for degradation. In eukaryotes, the major 3’ to 5’ ribonuclease is the RNA 
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exosome complex56. The multisubunit complex is recruited to the unprotected 3’ end of 
transcript through the RNA-induced silencing complex (RISC) after the RNA has undergone 
endonucleolytic cleavage by Ago256,57. The RNA exosome complex may also be recruited to a 
target transcript through the cofactor SKI758. SKI7 bridges the exosome to ski complexes and 
serves a role in nonstop decay by eliminating defective transcripts such as those containing 
aberrant translation termination58. An additional major player of 3’ to 5’ decay is the 
exoribonuclease, DIS3L2. After deadenylation as discussed above, TUTases polyuridylate the 3’ 
ends and create an optimal substrate for DIS3L259. The ribonuclease is also shown to play a role 
in apoptosis as well as cell differentiation59. The dysregulation of 3’ to 5’ decay leads to serious 
disease such as Perlman syndrome and kidney cancer primarily in children with DS3L2 
mutations59.  
 Figure 2. Simplified diagram of RNA decay pathways. 
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 Following decapping of the 5’ end, a transcript can now act as a substrate for 5’ to 3’ 
exonucleolytic decay. This pathway is primarily accomplished by the well-studied 
exoribonuclease, XRN1. XRN1 is a processive ribonuclease that favors RNAs containing a 
monophosphate on the 5’ end after decapping or endonucleolytic cleavage as described above60. 
It has been reported that XRN1 serves as a buffer for synthesis and degradation of mRNAs, thus 
suggesting the ribonuclease greatly contributes to regulating gene expression61,62.  
The Evolutionary Warfare Between Flaviviruses and Cellular RNA Decay 
The cell is well-equipped with a variety of antiviral proteins and pathways to overcome 
viral infections. Over time, viral proteins have evolved mechanisms of antagonizing these 
immune responses. For instance, NS5 in flaviviruses and nsP2 in alphaviruses are both 
nonstructural proteins that inhibit JAK-STAT signaling and thus inhibit host type-1 interferon 
(IFN-1) responses32,63. Flavivirus proteins have also been shown to inhibit molecules crucial to 
pattern recognition receptor (PRR) signaling. The E protein of WNV targets a major activator of 
Nf-κB signaling thus impairing IFN-1 induction and pro-inflammatory cytokines64. With the 
interferon response down, viruses can replicate more efficiently. Altogether, alphaviruses and 
flaviviruses have the ability to subvert the innate immune response. There is, however, another 
way to surpass antiviral pathways and that requires a disguise.  
While the normal function of the RNA decay pathway is to make sure that cellular 
mRNAs are undamaged and of high quality, this pathway has a second function: antiviral 
defense. During flavivirus infections after viral genomes are released into the cytoplasm for 
translation, the defective mRNA-looking transcripts are quickly noticed by the cellular RNA 
decay pathway. Seemingly, the viral RNAs have no chance against the key players of RNA 
decay as previously mentioned. However, flaviviruses have evolved to contain tricks up their 
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genomes called, subgenomic flavivirus RNA (sfRNA). Upon 5’ to 3’ decay by XRN1, the 
ribonuclease stalls on pseudoknot-like structures in the flavivirus 3’ untranslated region (UTR) 
of the genome65. Consequently, XRN1 activity is repressed, causing increased half-lives of 
uncapped RNAs, both cellular and viral, and dysregulation of the decay pathway while giving 
viral RNAs a chance to continue replicating65,66. It is hypothesized that sfRNA may act as decoys 
for factors of the decay pathway in humans and RNAi in mosquitoes allowing viral genomes to 
evade degradation, thus aiding in their replication67. SfRNA has also been shown to bind factors 
of innate type I interferon (IFN) response such as RIG-I and therefore suppressing both the 
protein and its associated IFN pathway68. It can also interact with the cellular proteins G3BP1, 
G3BP2, and CAPRIN that are involved in translating IFN-induced mRNAs69. Current research 
shows sfRNA is able to act as a “protein sponge” and sequester a variety of factors involved in 
RNAi and splicing, thus suppressing these crucial cellular pathways69. SfRNA plays various 
roles within the cell, affecting multiple pathways leading to dysregulation of crucial activities. 
Overall, sfRNAs formed during flavivirus infection have been shown to be critical in providing 
an optimal environment for viral replication and contributes significantly to the pathogenesis 
observed with these viruses. However, most of the studies to date have focused on the role of 
XRN1 in flavivirus infections, and little to no work has been done examining the roles of other 
components on restricting flavivirus infections. 
 Flaviviruses genomes are not the only viruses to have a way of antagonizing the immune 
response. Alphavirus 5’ and 3’ UTRs aid in increasing virulence and evading IFN responses. In 
the 5’ UTR, studies show that a single point mutation changing G to A at the third nucleotide of 
VEEV causes the virus to lose virulence in mice24,70. The mutated virus was shown to be more 
susceptible to IFN-α/β responses compared to the wildtype virus, thus leading to attenuation in 
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the mutant virus and suggesting the 5’ UTR plays a crucial role in viral evasion of host immunity 
by inhibiting binding of IFN- α/β factors70. In addition, alphaviruses contain a 5’ cap but lack 2’-
O-methylation, making it a target for the IFN-stimulated gene, IFIT-171. Instead of self-
methylating or stealing caps from host mRNAs, alphaviruses inhibit the binding of Ifit-1 by 
containing a thermodynamically stable stem loop structure at the 5’ end30. Mutations to this 
stem-loop creating a less stable structure increases the RNA’s susceptibility to Ifit-130. At the 
other end of the alphavirus genome, the 3’ UTR can bind cellular proteins such as HuR. By 
binding HuR with a high affinity, the protein prevents deadenylation and subsequent RNA 
decay72. The 3’ UTR also acts as a protein sponge, similar to the sfRNA previously described, 
and sequesters HuR leading to massive dysregulation of gene expression73. Overall, the 5’ and 3’ 
UTRs significantly affect viral replication however there are difference in structures and 
functions between alphaviruses and flaviviruses.  
Is DXO is a restriction factor for RNA viruses? 
 As flaviviruses and alphaviruses have evolved to evade or suppress cellular decay 
pathways and immune responses, cells have also developed methods to fight back. Here, we look 
at the decapping 5’ to 3’ ribonuclease, DXO, and its role in the antiviral response. Unlike XRN1, 
DXO utilizes capped 5’ ends as substrates and targets incompletely methylated 5’ caps42,48. DXO 
has the ability to decap the RNA substrate and subsequently degrade the transcript 5’ to 3’42,48.  
One study shows 2’-O-methylation of the 5’ cap protects RNAs from DXO activity74. As 
previously mentioned, flaviviruses contain a 2’-O-methylated 5’ cap which may be a method of 
evading DXO degradation. Interestingly, alphaviruses do not contain 2’-O-methylated caps 
causing question as to how they escape degradation by DXO.  
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The role of DXO in viral infections has never been studied, so it is currently unknown of 
DXO would play a role in viral infection. Therefore, the focus of this thesis is to begin defining 
if and how DXO influences flavivirus and alphavirus infection. Previous research has shown that 
DXO is a nuclear protein in HeLa and U2OS cell lines but it is unknown where DXO is localized 
within HEK cells47,75. Our studies have shown that DXO is a cytoplasmic protein in HEK cells 
and therefore co-localizes with viral RNAs. We first examined role DXO plays in flavivirus 
replication through analyzing viral RNA abundance and growth kinetics in wildtype (WT) and 
DXO CRISPR knockout (DXO KO) cell lines. Results showed a significant increase in viral 
replication and cytopathic effect in some viruses but not others thus indicating not all viruses are 
affected by DXO. We also observed the effect of DXO on a positive strand RNA virus from a 
different genus, SINV. Results show a significant increase in overall titer and viral RNA 
abundance in the absence of DXO compared to WT cells. We further examined DXO on a 
biochemical level to test if the exonuclease is inhibited by specialized RNA structures like 
XRN1. Recombinant DXO was added to radiolabeled 3’ UTR’s of DENV and Rift Valley fever 
virus (RVFV). Our data indicates that DXO does not create decay intermediates such as sfRNAs 
after degrading the DENV 3’ UTR. This data suggests the ribonuclease, unlike XRN1, can decay 
the highly structured 3’ UTRs without stalling. Overall, our results suggest that DXO does not 
play the same role in controlling viral replication of different viruses regardless of being in the 
same genus. The decapping exonuclease is shown to control the replication of positive strand 
RNA viruses in the cells and represents a new viral restriction factor. Further elucidation of 
mechanisms behind DXO activity during viral infections is necessary to shed light on how DXO 




Materials and Methods 
Cells and viruses. 
Wildtype (WT) and DXO-knockout (DXO-) human embryonic kidney (HEK) 293T cells 
were generously provided by Dr. Megerditch Kiledjian at Rutgers University while Vero cells 
were purchased from ATCC. DMEM medium (Thermo Fisher Scientific) with the addition of 
2.5 mM HEPES, 10% fetal bovine serum, and penicillin/streptomycin was used to culture the 
cells. Cells were propagated at 37˚C in 5% CO2. 
SINV (TE3’2J), WNV (subtype Kunjin, strain FLSDX), YFV (strain 17D), and ZIKV 
(strain PRVABC59) were used in this study. To produce the Kunjin E218A mutant, a novel virus 
launch system was used.  Briefly, PCR fragments containing the Cytomegelovirus (CMV) 
immediate early promoter (612 bp, fragment #1), the 5’ region of the Kunjin virus genome (8354 
bp, fragment #2), and the 3’ end of the Kunjin virus genome containing a Hepatitis Delta virus 
ribozyme (2822 bp, fragment #3) were produced using the New England Biolabs Q5 DNA 
polymerase system according to the manufacturer’s instructions76.  PCR primer sequences for 
each fragment were: 
Fragment #1 (CMV) 
Forward: 5’- tctatcggaaGATTATTGACTAGTTATTAATAGTAATCAATTACG  
Reverse: 5’- gcgaactactCGGTTCACTAAACGAGCTC  
 
Fragment #2 (5’ KUNV) 
Forward: 5’- tagtgaaccgAGTAGTTCGCCTGTGTGAG  
Reverse (E218A mutation): 5’- cccaatacatGGCATGTGTGGAATTCCG  
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Fragment #3 (5’ KUNV) 
Forward (E218A mutation): 5’- cacacatgccATGTATTGGGTGAGTCGAG  
Reverse: 5’- gtcaataatcTTCCGATAGAGAATCGAG  
 
The E218A mutation was engineered into the Fragment #2 reverse primer and Fragment 
#3 forward primer and mutant fragments were also produced. PCR products were gel extracted 
with the Qiagen Gel Extraction kit and quantified by UV spectrophotometry and agarose gel 
electrophoresis. To assemble the WT or E218A fragments, equal molar amounts of each 
fragment were mixed in a total DNA mass of 200ng for each virus in ultrapure water in a final 
volume of 15µl. An equal volume of New England Biolabs NEBuilder 2X Master Mix was 
added to the DNAs, and the reaction was incubated at 50oC for 4 hrs. To produce virus from the 
assembled DNAs, the assembled DNAs were transfected directly into Vero cells by adding 1µl 
of JetPrime transfection reagent to the assembly mixture, incubating at 22oC for 15 minutes, and 
adding the transfection mixture to 50% confluent Vero cells. cDMEM media was changed 24 hrs 
after transfection, and the cells were incubated for 6 additional days and monitored for 
cytopathic effect. Media was collected on day 6 as the P0 stock. Virus was amplified in a larger 
culture for 7 additional days and collected as the P1 stock. Finally, the P1 stock was used to 
infect a T150 flask of 50% confluent Vero cells for 7 days, media was collected and clarified of 
cellular debris, and clarified media frozen at -80oC as the P2 stock. The P2 stock was quantified 
for infectivity via focus forming assay, and the presence of the E218A mutation was verified by 
extracting RNA from the P2 stock, reverse transcribing and PCR amplifying the NS5 region of 
Kunjin virus using primers 5’GTTTATCCATAACATGGACTCTTGT and 
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5’GTAGAGGTTTTCCCACTGCTCT, and the sequence of the PCR amplicon determine by 
Sanger sequencing.    
Viral stocks were grown on Vero cells for several days until significant cytopathic effect 
was observed. Media was collected and centrifuged at 19,000 x g for 10 minutes to pellet cell 
debris. Virus-containing media was then aliquoted and stored at -80˚C. Viral titers were obtained 
through plaque and focus forming assays.   
Nuclear-Cytoplasmic Fractionation and Western Blots 
Cells were plated in 10 cm plate at 20% confluency and incubated overnight. Media was 
removed from plates and gently washed with 1XPBS. Cells were trypsinized and trypsin was 
diluted by adding equal volume DMEM. Cells were thoroughly mixed then pelleted at 300 x g 
for 5 minutes. Supernatant was discarded without disturbing the cell pellet. Cells were 
resuspended in 2 mL 1XPBS and re-pelleted under same conditions to ensure excess media is 
removed. Supernatant was discarded and cell pellet was resuspended in 1 mL NP-40 lysis buffer 
[0.5% NP-40, 10 mM Tris HCl pH 8.5, 1.5 mM MgCl2, 10 mM EDTA, 140 mM NaCl]. 
Suspended cells were transferred to a 1.7 mL Eppendorf tube and incubated on ice for 10 
minutes. Some of the whole cell lysate was saved as a control and set aside. Lysed cells were 
centrifuged at 500 x g for 5 minutes at 4˚C. Supernatant was saved as cytoplasmic fractions and 
stored on ice. The pellet containing nuclear fractionation was with NP-40 lysis buffer with 
inversion mixing and re-centrifugation at 500 x g. Supernatant was discarded and nuclear pellet 
was resuspended in 500 𝜇L H2O. Samples can be stored at -20˚C or used immediately for 
western blotting.  
Cytoplasmic and nuclear fractions were resolved on a 12% polyacrylamide SDS-PAGE 
gel for one hour at 120 V. Proteins were transferred to PVDF (Immobilin-P #IPVH0010) for one 
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hour at 100 V using Bio-Rad’s Mini Trans-Blot Cell system (#1703930) and 1X transfer buffer 
[25 mM Tris, 192 mM glycine, 10% methanol]. Blots were blocked with 2% non-fat dry milk in 
TBS-T for thirty minutes. Primary antibodies were added to the blocking buffer at appropriate 
dilutions and incubated on a rocker at 4 ˚C overnight (see Table 1 for antibody details). Blots 
were washed in 5 times in TBS-T for 5 minutes each wash. Blocking buffer with appropriate 
secondary antibody was added to the blot and incubated at room temperature for one hour. Wash 
steps were repeated. Blots were developed with SuperSignal West Dura Extended Duration 
Substrate using protocol (Thermo Scientific #34075). Images of blots were taken using the 
Biomolecular Imager from Azure Biosystems.  
WT vs. DXO- HEK Cell Growth Curve 
 WT and DXO- HEK cells were plated at 20% confluency in 12-well plates. Plates were 
incubated in optimal conditions previously mentioned and counted every 12 h for 72 h. Cells 
were trypsinized and diluted in Trypan Blue (Corning #25-900-CI). Live cells were counted 
using a hemocytometer and plotted using GraphPad Prism 8.  
Viral Infections. 
 For analysis of intracellular viral RNA abundance, 10 cm plates were seeded to 20% 
confluency with WT or DXO KO cells. The cells were infected with ZIKV at an MOI of 1 and 
incubated at 37˚C for 72 h. Media was discarded and 4 mL of Trizol (ThermoFisher Scientific) 
was added directly to the cells. Total RNA was extracted following the manufacture’s protocol 
and analyzed by digital PCR.  
SINV, WNV (subtype Kunjin), and YFV were used to infect WT and DXO- HEK 293T 
cells at a MOI of .01. SINV was incubated on the cells at 37˚C for 72 h. Virus-containing media 
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and cells were collected and stored in aliquots at -80˚C after 4, 8, 12, 24, 36, 48, 60, and 72 h 
post-infection. KUNV and YFV were incubated on the cells for seven days, collecting infectious 
media and cells every 24 h.  
Viral Titer Quantification by Focus Forming and Plaque Assay. 
Flavivirus titers for YFV, ZIKV, and WNV growth curves were quantified from media 
by focus-forming assay, as previously described77. DENV titers were quantified using a plaque 
assay. Baby hamster kidney (BHK) cells were used to seed 6-well plates at 90 to 95% 
confluency. Serial dilutions of infectious DENV media were made in PBS containing 1% 100X 
Ca2+, Mg2+ ions and 10% FBS. Media was aspirated from BHK cells and 250 𝜇L of each virus 
dilution was added to individual wells. Cells were incubated with diluted virus for one hour at 
room temperature on a rocker. 3 mL of an overlay containing equal volume sterile 2% agarose 
and 2X DMEM was added to each well. Once solidified, the plates were incubated for five days 
at 37˚C. 1 mL of 10% DMEM was added after two days of incubation to prevent cells from 
drying out. Plaques were stained overnight at 37˚C using 2 mL per well of 1:12 Neutral Red to 
PBS.  
Sindbis virus titers were quantified by plaque assay. 24-well plates were seeded with 
Vero cells and incubated overnight to achieve full confluency. Infectious media for Sindbis 
growth curve were serially diluted 10-fold and incubated on the Vero cells for 1 h at 37˚C. An 
overlay of an agarose-DMEM mixture [DMEM powder (Sigma-Aldrich), 
penicillin/streptomycin, 10% FBS, 4% NaHCO3] was added on top of cells and virus. The plates 
were incubated for 72 h at 37˚C. Cells were fixed with 10% formaldehyde before agarose-
DMEM was removed from wells. Cells were washed with PBS and stained with .1% crystal 
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violet (Sigma-Aldrich) for 10 min. Plaques were counted and calculated for each timepoint and 
reported as pfu/mL.  
In Vitro Transcription of Northern Probes and 3’ UTR Substrates 
 The 3’ UTR sequences of ZIKV, DENV, and RVFV were individually cloned into the 
pGEM4 (Promega) to be subsequently transcribed. The plasmid was transcribed to make the 
internally radiolabeled Northern probes and 3’ UTR substrates by using the SP6 polymerase 
(ThermoFisher Scientific). 0.5 mM UTP and the addition of α-32P- UTP (800 Ci/mmol). The SP6 
protocol was followed and incubated at 37˚C for three hours. The ZIKV 3’ UTR probe and 
radiolabeled 3’ UTR substrates underwent cleanup through a denaturing polyacrylamide gel 
purification. Radiolabeled 3’ UTRs were resolved on a 5% polyacrylamide gel containing 7 M 
urea. Bands were imaged by X-ray film and excised from the gel. Excised desired products were 
placed in a high salt concentration buffer (HSCB) [400 mM NaCl, 25 mM Tris-HCl pH 7.6, 
0.1% SDS] and RNA eluted overnight at room temperature. RNA was purified using a 
phenol/chloroform isoamyl alcohol (25:24:1) extraction and ethanol precipitation. RNA was 
resuspended in 20 𝜇L of double distilled H2O.  
Northern Blots 
5 𝜇g of total RNA during ZIKV infections was resolved on a 5% denaturing 
polyacrylamide gel in 1X TBE at 600 V until desired separation has occurred. The RNA was 
then transferred onto a nylon membrane at 10 V overnight (GE Healthcare #RPN203S) using a 
wet transfer apparatus at 4˚C. Following the transfer, the membrane was UV-crosslinked using 
the Stratagene UV Stratalinker Auto-Crosslink function. The membrane was washed using a 
Northern pre-wash buffer [0.1X SSC, 0.1% SDS] at 60˚C for one hour. The pre-wash buffer was 
discarded and the membrane was washed in Hybridization buffer [50% formamide, 5X SSC, 
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1.0% SDS, 0.1 mg/mL salmon sperm DNA, 5X DENHARdTS Reagent] for one hour at 60˚C. 
The ZIKV 3’ UTR Northern probe was added to 25 mL of Hybridization buffer and pre-warmed 
to 60˚C. Hybridization wash was discarded from the membrane and the Hybridization buffer 
containing the probe was added. The membrane was incubated with the probe at 60˚C overnight 
with gentle agitation. The buffer containing the probe was decanted and the membrane was 
washed twice with Low Stringency Buffer [0.1% SDS, 2X SSC] then twice with High 
Stringency Buffer [0.1% SDS, 0.2X SSC] for 15 min each at 60˚C. The membrane was 
subsequently exposed to a phosphor screen for one hour to overnight depending on signal 
intensity. The membrane was then imaged using the Biomolecular Imager from Azure 
Biosystems. 
Extracellular and Intracellular Viral RNA Quantification. 
Extracellular and intracellular total RNA was extracted from using TRIzol reagent 
(ThermoFisher Scientific) following the manufacturer’s protocol. The total RNA was then 
treated with DNase I (ThermoFisher Scientific) for twenty minutes at 37˚C. Phenol extraction 
and ethanol precipitation were used to remove DNase I and isolate total RNA. Total RNA quality 
was assessed using gel electrophoresis to visualize 18S and 28S rRNA to ensure no smearing of 
bands suggesting RNA degradation. 
Viral RNA abundance for Sindbis and West Nile virus was normalized and quantified 
using digital PCR (dPCR), as described previously [2]. 1 μg of total RNA was reverse 
transcribed and diluted 1:10 – 1:1000 fold before dPCR for accurate quantification. The 
following primers were used for dPCR: 
Forward GAPDH: 5’- AAGGTGAAGGTCGGAGTCAA 
Reverse GAPDH: 5’- AATGAAGGGGTCATTGATGG 
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Forward ZIKV: 5’- AGGATCATAGGTGATGAAGAAAAGT 
Reverse ZIKV: 5 - GCACCAATCTTAATGTTGTCAGG 
Forward genomic WNV: 5’- TGGACGGGGAATACCGACTTAGAGG 
Reverse genomic WNV: 5’- ACCCCAGCTGCTGCCACCTT 
Forward genomic SinV: 5’- CATCGGTGAGAGACCACCTT 
Reverse genomic SinV: 5’- AACCACGCCTTTGTTTCATC 
Cell Free RNA Decay Assays 
 Recombinant XRN1 (pET26b-XRN1) and DXO (pET28a-DXO) were transformed into 
BL21-DE3 cells and purified as previously described47,78. For the XRN1 reaction, approximately 
200,000 cpm of internally radiolabeled DENV or RVFV 3’ UTRs substrates were added to the 
reaction along with 1 𝜇L Ribolock RNase Inhibitor (ThermoFisher Scientific), 2 𝜇L of 10X 
NEBuffer 3 (New England Biolabs) and ddH2O for a final volume of 19 𝜇L. Approximately 0.06 𝜇g of purified XRN1 was added to the reaction. Instead of NEBuffer 3, the DXO RNA decay 
reaction consisted of 2 𝜇L of 10X IVDA-2 buffer [100 mM Tris-HCl, pH 7.6, 1 M KOAc, 20 
mM MgCl2, 0.50 mM MnCl2, 20 mM DTT, and 20 mM spermidine]. Approximately 0.07 𝜇g of 
recombinant DXO was added. All reactions were incubated at 37˚C. Four timepoints were taken 
from the reaction and stopped by placing it into HSCB. Phenol/chloroform extraction and 
ethanol precipitation techniques were used to purify the RNA. The RNA was resolved on a 5% 
denaturing polyacrylamide gel and exposed to a phosphor screen for one hour to overnight 
depending on the intensity of the bands. Phosphor screens were subsequently imaged using the 
Biomolecular Imager from Azure Biosystems. 
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DXO Over-Expression Cell Line 
 The p3XFLAG-CMV-10 vector was obtained through Sigma. Mammalian DXO was 
amplified from HEK cell extracted cDNA using PfuUltra II Fusion High-Fidelity DNA 
polymerase (Agilent) and the following primers: 
DXO Forward +EcoR1 cut site: GATCGAATTCGATCCCAGGGGGACCAAGAG 
Reverse DXO +BAMH1 cute site: TCGCGGATCCTATTTGGGAGAGGGAGTCTTGG 
Correct PCR product size was confirmed on 1% agarose gel and purified using Wizard 
SV Gel and PCR Clean-Up System (#A9281). The PCR product and vector were double digested 
using EcoR1 (NEB #R3101S) and BamH1 (NEB #R0136S). The digest product was then gel 
purified on a 1% agarose gel using the Wizard SV Gel and PCR Clean-Up System. The DXO 
insert and vector were ligated using the T4 DNA Ligase (NEB # M0202S). Plasmids were 
transformed into DH5α cells and plated on LB + ampicillin plates. Plates were incubated at 37˚C 
overnight. 5 mL LB + ampicillin cultures were grown up overnight using colonies from the 
plates. Plasmids were miniprepped using the QIAprep Spin Miniprep Kit (Qiagen #27104). 










DXO is a Cytoplasmic Protein 
 We first wanted to evaluate if the exonuclease is localized in the cytoplasm where viral 
RNA is commonly located. Previous data have shown that DXO is a nuclear protein in HeLa 
cells and U2OS cells but there are no publications regarding DXO localization in HEK cells. WT 
and DXO KO cells were subjected to nuclear and cytoplasmic fractionation to understand where 
DXO is localized within the cells. XRN2 and tubulin were used as positive controls and appeared 
in the nuclear and cytoplasmic fractions, respectively (Figure 3). DXO KO HEK cells were used 
as a negative control. DXO appeared in the cytoplasmic fraction in WT HEK cells. Based on the 
conclusion that DXO is co-localized in the cytoplasm with viral RNA, this data suggests that it is 
Figure 3. DXO is a cytoplasmic protein in HEK cells. Cytoplasmic and nuclear proteins from 
HEK cells were fractioned and analyzed via western blotting. Non-fractioned cell lysate (whole 
cell ctrl) was used as a positive control. Tubulin and XRN2 were positive controls for 
cytoplasmic and nuclear fractions, respectively. The DXO KO HEK cell line was also analyzed 
in the set of experiments to show no DXO is present compared to WT cells.  
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plausible that the 5’ to 3’ exonuclease plays a direct role in affecting viral replication without 
needing to re-localize. In addition, we were able to confirm that the DXO KO cell line did not 
express DXO. This DXO KO cell line along with the WT HEK cells were used in further 
experiments to study the role of DXO in flavivirus and alphavirus replication.  
DXO KO Cells Show a Lag in Replication Rate Compared to WT Cells  
Before using DXO KO cells in further experiments, we wanted to understand the differences in 
growth rates between the wildtype and mutant HEK cells. WT and DXO KO cells were counted 
over the course of 72 h and compared (Figure 5). Starting at 12 h, there were approximately 1.2-
fold more WT cells than DXO KO and 1.7-fold more by 72 h. Overall, linear regression showed 
a WT growth curve slope of .0136 and .01164 for DXO KO cells. Although DXO KO cells show 
a delay in growth shortly after being seeded, the CRISPR knockout cell line and WT cells have 
similar growth rates throughout the rest of the recorded time. Based on this data, it is necessary 
to consider growth rates when comparing viral titers or abundance of viral RNA. If DXO KO 
Figure 4. Plot of WT and DXO KO growth rates over 72 h. WT and DXO KO cells were plated 
in 12-well plates at approximately 20% confluency and counted using Trypan blue every 12 h. 
Each timepoint contains three replicates. Both cell line growth rates were plotted and compared 
against each other.  
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cells take slightly longer to begin replicating at a comparable rate to WT cells, then there will be 
fewer DXO KO cells at a given timepoint. If we observe an increase in virus replication in DXO 
KO cells compared to WT cells, then this difference may be even greater when taking cell line 
replication rates into account.  
Cells Lacking DXO Show a Significant Increase in ZIKV RNA Compared to WT Cells
 In these studies, we wanted to investigate the effect of DXO on flavivirus replication 
through analyzing intracellular RNA abundance. WT and DXO KO cells were infected with 
ZIKV at a MOI of 1.0. Intracellular ZIKV RNA abundance was quantified 72 h after infection of 
WT and DXO KO cells through extraction and analysis of total RNA by digital droplet PCR. 
Results showed an approximate 6-fold increase in viral RNA abundance in DXO KO cells 
compared to WT cells (Figure 6A). This increase in viral RNA abundance was confirmed in a 
(A) 
Figure 5. Quantification of ZIKV RNA abundance in WT vs. DXO KO cells. (A) Digital 
PCR Quantification of Relative Intracellular ZIKV RNA Abundance in WT and DXO KO 
Cells. Total RNA was extracted from infected HEK cells 72 hpi. Primers specific to the 
ZIKV genome were used to quantify relative abundance of ZIKV RNA present in WT and 
DXO KO cells. (B) Northern Blots of ZIKV Genomic RNA. Total RNA extracted was 
resolved on a 5% denaturing polyacrylamide gel and transferred to a nylon membrane for 
subsequent probing of viral RNA. Probes used were specific to the ZIKV 3’ UTR. One 
extra band that has not yet been identified appeared in the DXO KO cell line and has been 





northern blot using probes against the ZIKV 3’ UTR (Figure 6B). Visually there is an apparent 
increase in viral genome abundance in the DXO KO cells compared to WT cells. We conclude 
that DXO represses viral replication during ZIKV infection. In addition to the visual increase in 
viral RNA abundance, an extra band appears above the two sfRNAs. This larger viral RNA is 
currently unidentified but may suggest that DXO is necessary to degrade this RNA. Therefore in 
cells lacking DXO, the RNA decay pathway may be stalling on a certain area of the viral genome 
and thus creating a new decay intermediate.  
DXO Helps Maintain Sustained High Viral Titers During Flavivirus Infection 
 Based on the previous set of data, we wanted to examine if the increase in viral RNA 
abundance translated to an increase in viral titers. Additionally, we wanted to assess the growth 
kinetics of different viruses in the presence and absence of DXO in order to see if similar 
phenotypes are observed across the flavivirus genus. YFV and KUNV were used to infect WT 
and DXO KO cells at a MOI of 0.01. Infectious media was collected at each timepoint and viral 
titers were quantified by focus forming assays, as previously described79. YFV showed 
approximately a one-log increase in viral titers in DXO KO cells compared to WT cells on days 
two through four (Figure 7). Interestingly, there was no difference in KUNV titers observed 
during the exponential phase of viral growth. Both YFV and KUNV displayed a drastic decrease 
in viral titer starting on day five and four, respectively. These results suggest that DXO represses 
YFV replication. Images of the cells during KUNV infection were taken to observe for 
cytopathic effects (CPE). On day four post-infection, DXO KO cells showed significant signs of 
CPE and were not adhered to the flask while WT cells appeared alive. Visually the data suggests 
that cells lacking DXO undergo increased CPE during viral infection compared to cells 

















DXO Reduces Sindbis Virus Growth and Viral RNA Accumulation 
 We next wanted to determine if DXO affects positive-strand RNA viruses of a different 
genus from flaviviruses and thus selected the alphavirus, SINV. WT and DXO KO cells were 
infected with SINV at a MOI of 0.01 and media as well as cellular RNA was collected at each 
timepoint. Viral titers were quantified through plaque assays using the infectious media 
(A) 
(B) 
Figure 6. DXO affects the replication of YFV and maintains sustained high viral titers in 
YFV and KUNV. (A) YFV and KUNV titers in WT and DXO KO cell media infected with a 
MOI of 0.01. Infectious media from each timepoint was analyzed using a focus forming 
assay. The average pfu/mL of each timepoint was plotted over time with error bars 
representing standard error of the mean. (B) Microscope images of  WT and DXO KO cells 
infected with KUNV three- and four-days post-infection. Images of uninfected and infected 
cell lines are displayed.   
29 
 
collected. SINV titers were significantly higher in DXO KO cells compared to WT cells at 
twelve through forty-eight hours post-infection (Figure 7). Increases in both intracellular and 
extracellular viral RNA were observed in DXO KO cells compared to WT cells at forty-eight 
hours post-infection. We conclude that DXO represses SINV replication thus leading to 
decreased viral titers.  
What are the Potential Mechanisms Behind DXO as an Antiviral Effector? 
 Previous studies have shown that mRNA 5’ caps that are 2’-O-methylated are protected 
from DXO degradation47. Because flavivirus genomes contain a 2’-O-methylation in their 5’ 
Figure 7. DXO represses SINV replication. (A) SINV titers in WT and DXO KO cell media 
infected with a MOI of 0.01. Infectious media from each timepoint was analyzed using a focus 
forming assay. The average pfu/mL of each timepoint was plotted over time with error bars 
representing standard error of the mean. (B) Fold change of SINV intracellular RNA abundance 
48 hpi. Total RNA was extracted from infected HEK cells. Primers specific to the SINV genome 
were used to quantify relative viral RNA abundance in WT and DXO KO cells using digital 
droplet PCR.  (C) Digital droplet PCR quantification of extracellular viral RNA 48 hpi. Total 
RNA was extracted from infectious media and primers specific to the SINV genome were used 
to quantify viral RNA copies/mL. 
(C) 
(A) (B) * 
30 
 
caps, this potentially provides the viral RNA with a disguise to evade degradation by DXO. In 
order to further investigate, a mutant E218A KUNV was constructed that prevents the virus from 
2’-O-methylating the 5’ cap during replication of the genome74. This mutant virus was used to 
infect both WT and DXO KO cells at a MOI of 0.01 and infectious media was collected to 
quantify viral titer. No difference was observed in E218A KUNV replication rates between the 
WT and DXO KO cells (Figure 8) during the exponential phase of growth, although a reduction 
of titer was observed at days 4 and 5 in DXO KO cells compared to WT. Overall, the growth 
kinetics of the E218A mutant KUNV is very similar to that of the WT KUNV (Figure 8). We 
conclude that no differences were observed between WT and DXO KO cells as well as WT and 
E218A KUNV through growth kinetics. Intracellular viral RNA abundance might display a more 
comprehensive mechanistic picture than released viral titers and thus we cannot rule out that 2’-
O-methlyation of the first transcript base may still play a role in DXO evasion. 
 The well-known exonuclease, XRN1, stalls on highly structured 3’ UTR pseudoknots 
thus creating sfRNAs65. In collaboration with Phillida Charley in the Wilusz lab, we wanted to 
Figure 8. KUNV lacking 2'-O-methlyation on the first base of the transcript does not affect viral 
growth kinetics in WT and DXO KO cells. WT and DXO KO cells were infected at a MOI of .01 
with E218A KUNV. Infectious media was collected and analyzed using a focus forming assay. 




examine if DXO also stalls on these RNA structures to produce sfRNAs or if it degrades through 
the pseudoknots. Radiolabeled 3’ UTRs of DENV and the phlebovirus, Rift Valley fever virus 
(RVFV), were incubated with XRN1 and DXO under established conditions for each enzyme. 
Viral RNA products were examined on a polyacrylamide gel using phosphorescence. XRN1 
creates two decay intermediates on the DENV-2 3’ UTR and one decay intermediate on RVFV-
N that appeared after one minute of incubation (Figure 9). No apparent bands appeared after 
DXO was added to the 3’ UTRs, thus suggesting no decay intermediates were generated by the 
action of the enzyme. We conclude that DXO does not stall on pseudoknots located on the 3’ 












Figure 9. Mammalian DXO does not create decay intermediates. Data generated in 
collaboration with Dr. Phillida Charley, Dr. Jeff Wilusz Lab. The 3’ UTRs of DENV-2 
and RVFV-N were radiolabeled using α-32P- UTP and used as substrates for recombinant 
XRN1 and DXO. Arrows point to decay intermediates observed. Samples were taken at 
timepoints listed above the gel. The percentage of RNA remaining at timepoints taken 
during the reactions are listed below relative to the starting RNA substrate abundance 
labeled as 100%. The sizes of the starting RNA and the decay intermediates produced are 




 As flaviviruses and alphaviruses continue to threaten populations across the globe, the 
need for effective vaccines and antiviral therapeutics grows stronger. By understanding the 
details behind viral interactions with the cellular environment during infection, we can shed light 
on various targets for preventative care and treatments. Recent studies have demonstrated the 
critical roles of the RNA decay pathway during viral infections. XRN1 is the most well-known 
of the 5’ to 3’ exonucleases to be involved in degrading viral RNAs but stalls on pseudoknot- 
containing three helix junction structures located in certain viral 3’ UTRs65. Stalling of XRN1 
subsequently leads to dysregulation of mRNA transcripts, decrease in cellular responses to the 
viral infection, and formation of sfRNAs during flavivirus infection80. In this study we evaluated 
the effect of the decapping 5’ to 3’ exoribonuclease, DXO, on flavivirus and alphavirus 
replication.  
 There are few publications focused on the mammalian DXO and its general role within 
the cell. Previous publications have shown that the decapping 5’ to 3’ exonuclease is a nuclear 
protein in HeLa and U2OS cancer cell lines47,75. HEK cells were used in these studies however 
no information has been published on DXO localization in HEK cells. A nuclear-cytoplasmic 
fractionation was performed on the HEK cell line and analyzed using a western blot. This study 
showed that DXO is a cytoplasmic protein in HEK cells unlike in HeLa or U2OS cell lines. Our 
findings suggest that DXO is differentially localized in various cell lines. In addition, genomes of 
RNA viruses replicate within the cytoplasm during infection and therefore it is plausible for 
DXO to target the foreign RNAs for degradation. Based on our data, HeLa cell DXO may not  
affect viral RNA unless the exonuclease translocates from the nucleus to the cytoplasm during  
infections. To further understand the antiviral functions of DXO in HEK cells as well as in  
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different cell lines, it would be interesting to investigate viral replication rates in HeLa cells and  
HeLa DXO KO cells.   
 In order to study the effects of DXO on RNA virus replication, a CRISPR-based DXO 
knockout cell line in HEK cells was obtained through our collaborator, Mike Kiledjian, at 
Rutgers University48. We wanted to examine if there were any noticeable phenotypes in cells 
lacking DXO compared to WT cells that may affect further experiments. Overall results showed 
the two cell lines had similar growth rates. The DXO KO cell line did however appear to display 
a lag in growth which may be due to the mutant cell line’s inability to adhere quickly to the flask 
and respond to stress such as passaging of the cells. We concluded that the minor lag observed in 
DXO KO cell growth will not affect further experimentation and the overall growth rate is 
comparable to that of WT cells. Overall the lack of DXO should not affect cell growth or the  
accuracy of the results. Certain proteins are essential for cell survival and upon knocking out the  
protein, dysregulation occurs within the cell and may lead to a decreased cell viability. The data  
we have observed comparing WT and DXO KO cells suggests that the minor lag in growth will  
not interfere with further experimentation with viral infections.   
 Subsequent experiments infected WT and DXO KO cells with various flaviviruses to 
analyze the effects of DXO on viral replication. We found that following infection with ZIKV at 
a high MOI, intracellular viral RNA was significantly increased 72 h post-infection in DXO KO 
cells compared to WT cells. Interestingly, the Northern blot showed there was also an increase in 
intensity of sfRNA#1 and #2 in DXO KO cells compared to WT. The increase in sfRNA 
abundance within the cell could lead to increased cell dysregulation due as the decay 
intermediates sequester essential cellular proteins. The observed increase in decay intermediates 
formed in cells lacking DXO suggests that the decapping exonuclease may play a role in 
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degrading sfRNAs while XRN1 stalls on such structures. In addition to the observed increase in 
sfRNAs, an additional band appears above the two known decay intermediates. This band is 
larger than the two sfRNAs and suggests that without DXO, the RNA decay pathway stalls on a 
different area of the ZIKV viral RNA thus creating a new decay intermediate. It is possible that 
DXO works with XRN1 to overcome and degrade highly structured areas of the flavivirus RNA. 
Through understanding where on the viral genome the decay intermediate is forming, we can 
better comprehend the role DXO plays in aiding viral RNA degradation. Overall this experiment 
shows that DXO plays a role in suppressing flavivirus replication within the cell. Further 
experimentation with other flaviviruses is necessary to understand if the phenotype observed is 
ZIKV or flavivirus specific.  
 Growth kinetics of YFV and KUNV were analyzed in WT and DXO KO cells infecting 
with a lower MOI to better observe minor differences between the two cell lines. Over the course 
of the first few days there is a significant increase in YFV viral titers from DXO KO cell 
compared to WT cells while no difference is observed in KUNV titers. The growth kinetics 
suggest that DXO has an effect on YFV by reducing the viral titers but does not appear to 
influence the abundance of KUNV virions. In addition, infections using different viruses of the 
same genus do not seem to have the same phenotype in the presence and absence of DXO. 
 Curiously, both YFV and KUNV growth curves display a drastic decrease in viral titers 
on day five and four, respectively. The reasoning behind this reduction in both titers cannot yet 
be fully explained however, an increase in cytopathic effect and cell death was observed in DXO 
KO cells but not in WT cells on the days the titers decreased rapidly. This phenotype was 
observed microscopically and additional experiments are necessary to analyze apoptosis and 
necrosis incidences in both cell lines during infections. The increase in cytopathic effect may be 
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due to the unfolded protein response (UPR). Previous research has shown accumulation of 
unfolded flavivirus proteins on the endoplasmic reticulum (ER) induces stress and the UPR81. 
Too much accumulation of unfolded proteins on the ER can lead to significant dysregulation of 
translation machinery and cellular homeostasis, thus leading to rapid cell death. As our data has 
shown, there is a significant increase in intracellular flavivirus RNA in DXO KO cells which 
may lead to an increase in polyproteins on the ER and cell death due to dysregulation of host 
machinery. In order to test if the UPR is being induced, one could first analyze if an increase in 
expression of UPR components such as kinases and an increase in viral proteins occurs during 
infection through a Western blot. Based on our data, we hypothesize that UPR components will 
be greatly expressed in DXO KO cells and not WT cells during infection since an increase in 
viral RNA in the knockout cell line would potentially lead to a significant increase in unfolded 
polyprotein. If we observe such results, this will indicate that the increase in viral proteins may 
be inducing the UPR thus leading to cellular dysregulation and cell death. In addition, our data 
also has shown an increase in sfRNA during flavivirus infection in DXO KO cells. Previous 
studies have shown that sfRNA can function as a protein sponge within the cell by binding a 
multitude of important factors such as those involved in splicing, the RNA decay pathway, and 
the innate type I IFN response80. An increase in the accumulation of sfRNAs as seen in DXO KO 
cells may lead to a greater imbalance in mechanisms of cellular regulation and rapid cell death.  
 Our data shows that flaviviruses are affected by DXO but we wanted to test if other 
positive-strand RNA viruses of a different genus were influenced by the decapping exonuclease 
during infection. Results show that the amount of infectious SINV released from cells was  
significantly increased in DXO KO cells compared to WT cells and there was a corresponding 
increase in extracellular viral RNA as well. This study suggests that DXO reduces the abundance 
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of infectious SINV virus being released from the cell and can be confirmed through the reduction 
in extracellular SINV RNA. Additionally, intracellular SINV RNA was increased in the absence 
of DXO. Altogether, we can conclude that DXO plays a significant role in suppressing the 
overall replication of SINV through reducing the abundance of intracellular RNA and thus 
reducing viral titer. This study suggests that DXO affects the replication of positive-strand RNA 
viruses of different genera however a more extensive variety of RNA viruses must be tested in 
the presence and absence of DXO.  
 Thus far we have shown that DXO plays a role in positive-strand RNA virus replication, 
but the mechanistic details behind the exonuclease have yet to be uncovered. As positive-strand 
RNA viral genomes localize within the cytoplasm, it is critical for these RNAs to have a method 
of evading DXO degradation. Shedding light on how flaviviruses and alphaviruses evade DXO 
will also elucidate how they are targeted by DXO. A recent publication from a collaboration 
between the Geiss and Bisaillon labs shown that 2’-O-methylation of the 5’ cap can protect 
mRNAs from DXO degradation47. Interestingly, flaviviruses have evolved to have a 2’-O-
methylated 5’ cap that has been shown to help evade cellular sensing molecules such as IFIT, 
and the presence of 2’O-methylation on flavivirus genomes could provide a potential mechanism 
of eluding the decapping exonuclease74. Additionally, alphaviruses do not have 2’-O-methylated 
5’ caps but may use a different means of DXO evasion. In order to further examine if 2’-O-
methylation protects flaviviruses from DXO degradation, an E218A mutant of KUNV was 
constructed and used to infect WT and DXO KO cells. Growth kinetics of the mutant virus were 
similar to that of the wildtype KUNV. Due to wildtype KUNV not displaying a difference in 
growth rates between WT and DXO KO cells, analyzing if the lack of 2’-O-methylation affects 
viral titer is not possible. However, it is possible that 2’-O-methylation may play a role in 
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protecting other flavivirus genomes that show different growth rates in DXO KO cells (such as 
YF).  The differences in RNA structures between flaviviruses and alphaviruses may explain why 
there are differences in growth kinetics in the presence and absence of DXO. Further 
experimentation mutating 2’-O-methylation or RNA structures in other viruses such as YFV or 
ZIKV may provide more insight and display more of a change in growth rates compared to the 
wildtype viruses.   
Based on the decapping and 5’ to 3’ exonuclease activity of DXO, we hypothesized that 
DXO can degrade capped viral RNA but may stall on the 3’ UTR pseudoknots similar to XRN1. 
Previous data has shown that yeast DXO does create decay intermediates when added to various 
positive-stranded plant virus and mosquito-borne flavivirus RNA82,83. However, the yeast DXO 
used in the published data is a weak homolog of the mammalian DXO used in our studies. To 
understand how DXO interacts with viral RNAs, 3’ UTRs of DENV and RVFV were 
radiolabeled and incubated with the exonuclease. XRN1 was used as a positive control as it is 
well-known the exonuclease stalls on the pseudoknots of viral 3’ UTRs. As expected, XRN1 
created two RNA decay intermediates when incubated with DENV and one decay intermediate 
appeared with RVFV. Interestingly, no decay intermediates formed when the same viral 3’ UTRs 
were incubated with DXO. Our data suggests that DXO does not stall on the pseudoknots like 
XRN1 and has the ability to degrade sfRNAs during flavivirus infection. We previously showed 
cells lacking DXO display an increase in genomic and sfRNA abundance during flavivirus 
infection. Altogether, the increase in sfRNA may explain the increase in cytopathic effect and 
rapid cell death in the absence of DXO during infection. Additional experimentation using 
radiolabeled 5’ UTRs or whole viral genomes may show if DXO stalls on different areas of viral 
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genomes. It is possible that DXO and XRN1 work together to pick up the degradation slack 
when one or the other stall.  
Overall the goal of these studies was to elucidate the role of DXO during positive-strand 
RNA virus infection. Results show that DXO does affect certain viruses such as ZIKV and YFV 
by suppressing their replication however, there are viruses of the same flavivirus genus such as 
KUNV that do not appear to be influenced by DXO. Our data suggests that DXO reduces the 
abundance of viral RNA intracellularly and extracellularly during ZIKV and YFV infections 
leading to a reduction in viral titers. Additionally, we demonstrated that DXO does affect the 
replication of positive-strand RNA viruses of other genera through showing a decrease in 
intracellular and extracellular SINV RNA and viral titer occurs in the presence of DXO. 
Mechanisms of DXO may include targeting viral RNAs through the lack of 2’-O-methlyation in 
the 5’ cap however we observed no difference in the wildtype KUNV growth kinetics compared 
to the E218A KUNV.  Results also suggested that DXO does not stall on pseudoknots of the 3’ 
UTR like XRN1 and therefore can degrade sfRNAs during flavivirus infection.  
Future experimentation is necessary for beginning to understand DXO’s role as an RNA 
virus restriction factor. In order to show that DXO is responsible for the effects on viral growth, 
we have constructed a plasmid to re-express DXO in the DXO KO cell line. We hypothesize that 
by infecting knockout cells that have been transfected with the DXO expression plasmid, we will 
see a decrease in viral titers and RNA abundance comparable to what we have observed in WT 
cells.  These experiments have yet to be completed but the plasmid expressing DXO has been 
constructed. In addition, we plan on investigating changes in intracellular and extracellular viral 
RNA during each infection such as what we have shown with SINV. Although KUNV did not 
display a change in viral growth kinetics during infection of WT and DXO KO cells, we did 
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observe a rapid reduction in viral titers a few days post-infection. KUNV may have more of an 
intracellular effect in WT and DXO KO cells and analyzing abundance of viral RNA could 
determine if DXO is reducing viral genome copies. Due to the lack of change observed in 
wildtype and E218A KUNV titers in WT and DXO KO cells, we also plan to make a similar 
mutation using YFV or ZIKV where the titers are noticeably different. Next, as we have shown 
DXO does not stall on viral 3’ UTR structures, we would like to examine the exonuclease’s 
ability to degrade viral 5’ UTRs. There may be structures that stall DXO but not XRN1, 
potentially making it crucial for the two 5’ to 3’ exonucleases to work together to degrade viral 
RNAs. Finally, the growth kinetics vary from virus to virus but this inconsistency may be 
explained through adaptation of the DXO KO cell line. Recently it has been published that 
knockout cell lines over time can compensate for the loss of protein function through 
differentially expressing other genes84. In order to test if the DXO KO cell line has adapted to the 
loss of DXO, we plan on comparing viral RNA abundances through infecting DXO KO and 
knockdown (DXO KD) cells. Knockdown cells will be made through transfecting WT HEK cells 
with siRNAs specific to DXO. If we observe significant differences between the DXO KO and 
DXO KD cells then this may be indicative of the knockout cells having adapted and we will need 
to change our methods to using knockdown cells.  
To summarize, we concluded that the decapping 5’ to 3’ exonuclease can influence the 
replication of certain positive-strand RNA viruses. Due to the lack previous research regarding 
mechanisms of DXO in the cell and during viral infections, this data represents the first steps 
towards understanding DXO’s potential role as a novel antiviral factor. These studies warrant 
further experimentation to comprehend the mechanisms of DXO as well as how virus growth 
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